Future Directions and Tailored Treatments in TTP Management

Disclosure of relevant financial relationship: Dr. Mazepa received honoraria from Sanofi.

Timestamps:

00:00 Intro

00:52 Why is it important for physicians to have some understanding about TTP?

04:26 What’s new in this immune TTP area?

08:57 If you have a new patient show up, you do caplacizumab and plasma exchange together or are there certain patient populations, like certain characteristics who would or would not get this medication? 

11:29 I was wondering if you could elaborate a little bit more about these chronic complications?

16:32 Do you think there is a role for repeat testing of ADAMTS13 on these patients in chronic phase, or is that an area that is unknown at this point?

18:53 What do you see on the horizon, what do you think the future looks like for TTP?

21:36 Outro

Resources:

Stroke and TTP (Hopkins group led by Dr. Shruti Chaturvedi):  https://ashpublications.org/blood/article/134/13/1037/374919/Reduced-ADAMTS13-activity-during-TTP-remission-is

Cognitive impairment in TTP:

(Ohio State and London TTP group collaboration) https://ashpublications.org/blood/article/134/13/1037/374919/Reduced-ADAMTS13-activity-during-TTP-remission-is

(OK Registry, Dr. James George) 

https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.24060